

RESEARCH

Open Access



# Children with *Plasmodium vivax* infection previously observed in Namibia, were Duffy negative and carried a c.136G > A mutation

Daniel Hosea Haiyambo<sup>1</sup>, Larysa Aleksenko<sup>2</sup>, Davies Mumbengegwi<sup>3</sup>, Ronnie Bock<sup>4</sup>, Petrina Uusiku<sup>5</sup>, Benoit Malleret<sup>6,7,8,9</sup>, Laurent Rénia<sup>10,11</sup> and Isaac Kweku Quaye<sup>12\*</sup>

## Abstract

**Background:** In a previous study, using a molecular approach, we reported the presence of *P. vivax* in Namibia. Here, we have extended our investigation to the Duffy antigen genetic profile of individuals of the same cohort with and without *Plasmodium* infections.

**Methods:** Participants with *P. vivax* (n = 3), *P. falciparum* (n = 23) mono-infections and co-infections of *P. vivax*/*P. falciparum* (n = 4), and *P. falciparum*/*P. ovale* (n = 3) were selected from seven regions. Participants with similar age but without any *Plasmodium* infections (n = 47) were also selected from all the regions. Duffy allelic profile was examined using standard PCR followed by sequencing of amplified products. Sequenced samples were also examined for the presence or absence of G125A mutation in codon 42, exon 2.

**Results:** All individuals tested carried the – 67 T > C mutation. However, while all *P. vivax* infected participants carried the c.G125A mutation, 7/28 *P. falciparum* infected participants and 9/41 of uninfected participants did not have the c.G125A mutation. The exon 2 region surrounding codon 42, had a c.136G > A mutation that was present in all *P. vivax* infections. The odds ratio for lack of this mutation with *P. vivax* infections was (OR 0.015, 95% CI 0.001–0.176; p = 0.001).

**Conclusion:** We conclude that *P. vivax* infections previously reported in Namibia, occurred in Duffy negative participants, carrying the G125A mutation in codon 42. The role of the additional mutation c.136 G > A in exon 2 in *P. vivax* infections, will require further investigations.

**Keywords:** Duffy gene mutations, Namibia, *Plasmodium vivax*

## Background

The life cycle of *Plasmodium* species in human hosts is initiated when an infected *Anopheles* mosquito injects sporozoites into the skin [1–3]. A fraction of the sporozoites move from the skin to circulation and take residence in the liver [4]. Here, the sporozoites multiply

extensively to generate thousands of merozoites. Next, liver merozoites enter the circulation and infect red blood cells (RBCs) and initiate the erythrocytic cycle [5]. In RBCs, erythrocytic schizogony goes through a ring stage (immature trophozoites), mature trophozoites and merozoites stages, which is repeated overtime. This stage is responsible for the clinical symptoms of infection, due in part to RBCs lysis and release of their contents into the blood stream leading to a pro-inflammatory immune response [6]. *Plasmodium vivax* (*P. vivax*) is unique in

\*Correspondence: isaac.quaye@regent.edu.gh

<sup>12</sup> Faculty of Engineering, Computer and Applied Sciences, Regent University College of Science and Technology, Dansoman, P. O. Box DS 1636, Accra, Ghana

Full list of author information is available at the end of the article



© The Author(s) 2021. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

that it has preference for immature reticulocytes during its erythrocytic cycle [7].

Duffy antigen receptor for chemokines (DARC) also called cluster of differentiation 234 (CD234) or atypical chemokine receptor (ACKR) is a receptor for a family of proinflammatory chemokines [8–10]. It was discovered to be a receptor for *P. knowlesi* and *P. vivax* and on the surface of RBCs in the 1970's [11]. It is also present on the surface of endothelial cells [12]. The DARC glycoprotein is encoded by the *FY* gene. Two codominant alleles *FY*\*A and *FY*\*B exist. These alleles produce the respective antigens *Fy*<sup>a</sup> and *Fy*<sup>b</sup>, which differ by a point mutation at position c.125G>A [13]. The Duffy negative/null antigen *Fy*<sup>(a-b-)</sup> is associated with a cI-67 T>C mutation on the GATA-1 transcription factor binding motif of the *Fy*\*A/B genes [14]. The mutation on *Fy*<sup>b</sup> is commonly seen in sub-Saharan Africans, while the *Fy*<sup>a</sup> mutation is common in Papua New Guineans [15, 16]. The null mutation on the *Fy*<sup>b</sup> allele was thought to be responsible for resistance of invasion of reticulocytes by *P. vivax* in sub-Saharan Africans [17]. However, there have been cumulative evidence using microscopy and/or molecular tools for the presence of *P. vivax* parasites in Duffy negative individuals in Sub-Saharan Africans [18, 19]. Since most of these studies were performed with subjects who had mostly no travel history to known endemic areas, this raises the question as to whether *P. vivax* is now emerging, having adapted to invade reticulocytes independent of DARC. Alternatively, it is possible that *P. vivax* infection did always occur in Duffy negative individuals, but its diagnosis was overlooked.

As a first approach to assess the prevalence of *P. vivax* infection in Duffy negative infected people, active case detection needs to be done across sub-Saharan Africa. This will be the basis of the understanding of *P. vivax* bionomics allowing comprehensive studies of invasion of reticulocytes and survival in its human host.

We recently reported the identification of *P. vivax* in Namibia [20]. Here, we have followed up to assess the Duffy status of the subjects who were infected. Our results add to the growing evidence that *P. vivax* infected individuals can be Duffy negative.

## Methods

### Study sites and population selection

The details of the sample selection are as previously published [20]. Samples from the following regions respectively grouped into infected and uninfected, were included: Kunene (0:8), Omusati (3:8), Oshana (2:10), Ohangwena (7:5), Kavango West (2:2), Kavango East (17:7) and Zambezi (Caprivi) (2:7). *Plasmodium* infected participants previously published were selected and uninfected with similar ages were also selected. The

*Plasmodium* infected participants totaled 33 while 47 were uninfected. The *Plasmodium* infected participants consisted of the following categories: *P. vivax* mono-infection (n=3), *P. falciparum* mono-infection (n=23), *P. vivax/P. falciparum* mixed infection (n=4) and *P. falciparum/P. ovale* mixed infection (n=3).

### Ethics statement

The study was approved by the Ministry of Health and Social Services (MOHSS) Ethical Committee, Namibia. All parents/guardians provided informed consent on behalf of all participants. Where necessary, assent was also obtained from the child before sample collection.

### Blood sample collection

The details of the procedure are as published previously [20]. In brief, an aliquot of 1.5–2.5 ml venous blood was collected into EDTA tubes and centrifuged at 3000 rpm for 5 min to separate the buffy coat, plasma and red blood cells into separate tubes. These were then stored at – 20 °C and later transferred to – 80 °C until analyzed.

### Laboratory analyses

#### DNA extraction

Genomic DNA was extracted from pelleted red blood cells using the automated Hamilton Star Microlab Workstation (Hamilton Bonaduz AG, Bonaduz, Switzerland) with the Machery and Nagel 96 blood DNA extraction kit. The starting blood sample was 200 µl of the packed and thawed red blood cells (RBCs), and final DNA elution volume of 120 µl sterile PCR-grade water.

#### Molecular detection of DARC

All detection assays were single-plexed and run in a high throughput 96 well plate Applied BioSystem GeneAmp 9700 PCR system, Singapore. Primers were ordered from Eurogentec, Liege, Belgium. All PCR amplification reactions were carried out in a total volume of 50 µl. For the standard PCR amplification reaction, 2.5 µl of DNA extracted from pelleted red blood cells was used, together with the KOD hotstart enzyme and the reaction mix was obtained from Sigma Chemical (Merck, Darmstadt, Germany). The amplified products were analyzed on 1.5% agarose gels by electrophoresis, followed by visualization on a UVP Geldoc-it Imager TS 310 (Cambridge, UK) after ethidium bromide staining. The amplified products were subsequently sent to Inqaba Biotech™, Pretoria, South Africa, for sequencing on both strands. Sequencing was done 2 × to confirm the observed mutation. The PCR cycling parameters for the primary amplifications were as follows: Initial denaturation at 95 °C for 2 min, then 30 cycles each of denaturation at 95 °C for 20 s, annealing at 62 °C for 10 s, extension at 70 °C for

11 s and a final hold at 4 °C. The primers had a final concentration of 0.2 μM with sequences of: Forward: CTC ATTAGTCCTTGGCTCTTAC and Reverse: AGCTGCTTCCAGGTTGGCAC, and AGCTGCTTCCAGGTTGGCAT. The amplified products were 711 bp.

**Statistical analysis**

Data were entered in an Excel data sheet and IBM Corp SPSS version 26 (IBM Corp. Released 2019. IBM Armonk, NY: USA) was used for analysis. Descriptive statistics and appropriate measures of central tendency were provided for relevant demographic covariates. Multinomial logistic regression was used to assess association of a mutation with a risk of infection with a *Plasmodium* parasite. A p value < 0.05 was considered significant.

**Results**

The median ages of the *Plasmodium* infected and uninfected individuals were respectively, 5 years (25–75 percentile, 2–8 years) and 6 years (25–75 percentile, 4–7 years). Data was obtained for all samples at the – 67 T>C locus. Similarly, data was obtained for *Plasmodium* infected participants at the c.125G>A and c.136G>A locus. However, in uninfected participants, 41/47 sequence reads were obtained at the c.125G>A and c.136G>A locus (Table 1). *P. vivax* infected participants (5/7) were Duffy negative (– 67 T>C mutation) as were all other *Plasmodium* infected individuals tested (Fig. 1A). The remaining two *P. vivax* samples could not be examined because of insufficient DNA. All *P. vivax* infected participants had the c.125G>A mutation (Fig. 1B). However, 9/41 of the *Plasmodium* uninfected participants (6 samples reads were not good within the region) and 7/28 of the *P. falciparum* infected participants (Table 1), had the FY\*A genotype (G at c.125 in exon 2) (Fig. 1B). There was a c.136 G>A mutation in

exon 2 that was present in all *P. vivax* infections (5/7). The odds ratio for lack of the mutation with *P. vivax* infection was (OR 0.015, 95% CI 0.001–0.176; p = 0.001).

**Discussion**

The present study compliments our previous investigation reporting the presence of *P. vivax* in Namibia [20]. The data clearly shows that the *P. vivax* infections previously observed in children, occurred in Duffy negative individuals. The observed mutation at c.136G>A occurring together with *P. vivax* Duffy negative infections in the FY\*B allele needs to be examined further, as to whether it has any significant role in the infection dynamics of *P. vivax*. This mutation has not been previously published, to the best of our knowledge. Other rare DARC polymorphisms that have been reported are the c.265C>T mutation in the FY\*B allele leading to the FY\*X allele, which has a reduced expression of the gene by 90% [21], and the c.298G>A mutation resulting in a codon change from Ala100Thr [22], that reduces the expression of the Duffy antigen in erythrocytes. It is also interesting that none of the *P. vivax* infected participants carried a FY\*A allele. *P. vivax* malaria is less benign than previously thought and considering that its life cycle is complicated by hypnozoites and early gametocyte release [23], the reports of the emergence of *P. vivax* in sub-Saharan Africa are a cause for concern. In Southern America it has been observed that recurrent infections of *P. vivax* frequently occur, even in subjects who had received full radical cure with primaquine [24, 25]. This shows that elimination of *P. vivax* is a difficult task requiring the National Malaria Control Programs (NMCPs) in African countries to plan accordingly.

The recent detections of *P. vivax* infections in Duffy-negative individuals suggest that the resistance associated with Duffy antigen negativity by *P. vivax* to reticulocyte infection is incomplete. [18]. The precise function of DARC on erythrocytes has not been deciphered. In general, however, it is known to be associated with the modulation of chemokine levels locally and systemically, to dampen inflammatory response [26, 27]. As to how this can impact parasite invasion and survival in the reticulocyte or erythrocyte is unknown. It has been reported that plasma and serum chemokine levels differ between individuals with FY\*A and FY\*B alleles [28]. The FY\*B allele was observed to have a lower expression of the Duffy antigen than FY\*A allele [29], although there was no effect on the binding affinities for chemokines. More data is required, examining new mutations in individuals infected or not infected with *Plasmodium* species to further understand the links with chemokine expression and

**Table 1** Summary of the numbers of participants with mutations at – 67 T>C, c.125 G>A and c. 136 G>A for *Plasmodium* infected and uninfected participants

Mutations	<i>Plasmodium</i> infected				Uninfected
	<i>Pv</i>	<i>Pf/Pv</i>	<i>Pf</i>	<i>Pf/Po</i>	
– 67 T>C	3 (3) <sup>a</sup>	2 (2)	23 (23)	3 (3)	47 (47)
c.125G>A	3 (3)	2 (2)	17 (23)	2 (3)	32 (41)
c.136G>A	3 (3)	2 (2)	1 (23)	0 (3)	1 (41)

*Pv*: *P. vivax*; *Pf*: *P. falciparum*; *Po*: *P. ovale*.

<sup>a</sup> Numbers in bracket indicate the good sequence reads obtained



inflammatory responses and how that relates to *P. vivax* entry into reticulocytes.

## Conclusion

The emergence of *P. vivax* infections in Duffy negative individuals in sub-Saharan Africa is a cause for concern. Namibia joins the list of these countries, which requires serious attention on the malaria elimination and eradication agenda of sub-Saharan Africa and partners.

## Abbreviations

RBCs: Red blood cells; DARC: Duffy antigen receptor for chemokines; CD234: Cluster of differentiation 234; ACKR: Atypical chemokine receptor; GATA: DNA binding sequence by transcription factors; FY: Duffy glycoprotein gene; MOHSS: Ministry of Health and Social Services; EDTA: Ethylene-diamine tetra acetic acid; PCR: Polymerase chain reaction; KOD: A DNA polymerase; UVP: Ultra violet protection; NMCP: National Malaria Control Program.

## Acknowledgements

The authors acknowledge the support of the National Malaria Control Program of Namibia (NMCP), the work of nurses Mrs Foibe Kalipi and Lucia Nghishongwa in sample collection. We acknowledge all subjects who agreed to participate in the work. The authors thank the Singapore Immunology Network (SIgN) flow cytometry core headed by Dr Anis Larbi, particularly Ivy Low, Seri Mustafah, and Nurhidaya Shadan. WWARN is acknowledged for forging the collaboration with SIgN.

## Author's contributions

IKQ: Conceptualization. IKQ, DHH, PU, DM, LA, RB, BM, LR: Protocol/project development. IKQ: Project administration. IKQ, PU, DM, LA, BM, LR, RB: Data collection and management. IKQ, LA, DHH, BM, LR: Data analysis. IKQ, DHH, LA, LR, DHH, BM, PU, DM, RB, DHH: Manuscript writing/editing. All authors read and approved the final manuscript.

## Funding

Merck Global Health Institute.

## Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available due to restrictions imposed by the Ethical Committee of the Ministry of Health and Social Services, but are available from the corresponding author on reasonable request.

## Declarations

### Ethics approval and consent to participate

The study was approved by the MOHSS Ethical Committee, Namibia. All methods were performed in accordance with the prevalent guidelines and regulations. All parents/guardians provided informed consent on behalf of all participants. Where necessary, assent was also obtained from the child before sample collection.

### Consent for publication

Not applicable.

### Competing interests

None.

### Author details

<sup>1</sup>Department of Biochemistry and Microbiology, University of Namibia School of Medicine, Windhoek, Namibia. <sup>2</sup>Department of Clinical Sciences, University of Lund, Lund, Sweden. <sup>3</sup>Multidisciplinary Research Center, University of Namibia, Windhoek, Namibia. <sup>4</sup>Department of Biology, University of Namibia, Windhoek, Namibia. <sup>5</sup>Ministry of Health and Social Services Department of Biology, National Vector Borne Disease Control Program, Windhoek, Namibia. <sup>6</sup>Department of Microbiology and Immunology, Yong

Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. <sup>7</sup>Immunology Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. <sup>8</sup>Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore. <sup>9</sup>Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A\*STAR), Biopolis, Singapore. <sup>10</sup>A\*STAR ID Labs, Agency for Science, Technology and Research (A\*STAR), Biopolis, Singapore. <sup>11</sup>Lee Kong Chian School of Medicine, Nanyang Technological University, 11 Mandalay Road, Singapore 308232, Singapore. <sup>12</sup>Faculty of Engineering, Computer and Applied Sciences, Regent University College of Science and Technology, Dansoman, P. O. Box DS 1636, Accra, Ghana.

Received: 24 May 2021 Accepted: 13 August 2021

Published online: 21 August 2021

## References

- Beier JC. Malaria parasite development in mosquitoes. *Annu Rev Entomol.* 1998;43:519–43.
- Frevert U. Sneaking in through the back entrance: the biology of malaria liver stages. *Trends Parasitol.* 2004;20(9):417–24.
- Kappe SH, Kaiser K, Matuschewski K. The *Plasmodium* sporozoite journey: a rite of passage. *Trends Parasitol.* 2003;19(3):135–43.
- Cowman AF, Kappe SH. Microbiology. Malaria's stealth shuttle. *Science.* 2006;313(5791):1245–6.
- Cowman AF, Berry D, Baum J. The cellular and molecular basis for malaria parasite invasion of the human red blood cell. *J Cell Biol.* 2012;198(6):961–71.
- Bannister L, Mitchell G. The ins, outs and roundabouts of malaria. *Trends Parasitol.* 2003;19(5):209–13.
- Malleret B, Li A, Zhang R, Tan KS, Suwanarusk R, Claser C, et al. *Plasmodium vivax*: restricted tropism and rapid remodeling of CD71-positive reticulocytes. *Blood.* 2015;125(8):1314–24.
- Demogines A, Truong KA, Sawyer SL. Species-specific features of DARC, the primate receptor for *Plasmodium vivax* and *Plasmodium knowlesi*. *Mol Biol Evol.* 2012;29(2):445–9.
- Horuk R. The Duffy antigen receptor for chemokines DARC/ACKR1. *Front Immunol.* 2015;5(6):279.
- Bachelier F, Ben-Baruch A, Burkhardt AM, Combadiere C, Farber JM, Graham GJ, et al. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. *Pharmacol Rev.* 2013;66(1):1–79.
- Miller LH, Mason SJ, Dvorak JA, McGinniss MH, Rothman IK. Erythrocyte receptors for (*Plasmodium knowlesi*) malaria: Duffy blood group determinants. *Science.* 1975;189(4202):561–3.
- Chaudhuri A, Polyakova J, Zbrzezna V, Williams K, Gulati S, Pogo AO. Cloning of glycoprotein D cDNA, which encodes the major subunit of the Duffy blood group system and the receptor for the *Plasmodium vivax* malaria parasite. *Proc Natl Acad Sci U S A.* 1993;90(22):10793–7.
- Iwamoto S, Omi T, Kajii E, Ikemoto S. Genomic organization of the glycoprotein D gene: Duffy blood group Fya/Fyb alloantigen system is associated with a polymorphism at the 44-amino acid residue. *Blood.* 1995;85(3):622–6.
- Tournamille C, Colin Y, Cartron JP, Le Van KC. Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. *Nat Genet.* 1995;10(2):224–8.
- Parasol N, Reid M, Rios M, Castilho L, Harari I, Kosower NS. A novel mutation in the coding sequence of the FY\*B allele of the Duffy chemokine receptor gene is associated with an altered erythrocyte phenotype. *Blood.* 1998;92(7):2237–43.
- Hoher G, Fiegenbaum M, Almeida S. Molecular basis of the Duffy blood group system. *Blood Transfus.* 2018;16(1):93–100.
- Miller LH, Mason SJ, Clyde DF, McGinniss MH. The resistance factor to *Plasmodium vivax* in blacks. The Duffy-blood-group genotype FyFy. *N Engl J Med.* 1976;295(6):302–4.
- Gunalan K, Niangaly A, Thera MA, Doumbo OK, Miller LH. *Plasmodium vivax* infections of Duffy-negative erythrocytes: historically undetected or a recent adaptation? *Trends Parasitol.* 2018;34(5):420–9.

19. Menard D, Barnadas C, Bouchier C, Henry-Halldin C, Gray LR, Rat-simbasoa A, et al. *Plasmodium vivax* clinical malaria is commonly observed in Duffy-negative Malagasy people. *Proc Natl Acad Sci U S A*. 2010;107(13):5967–71.
20. Haiyambo DH, Uusiku P, Mumbengegwi D, Pernica JM, Bock R, Malleret B, et al. Molecular detection of *P. vivax* and *P. ovale* foci of infection in asymptomatic and symptomatic children in Northern Namibia. *PLoS Negl Trop Dis*. 2019;13(5): e0007290.
21. Olsson ML, Hansson C, Avent ND, Akesson IE, Green CA, Daniels GL. A clinically applicable method for determining the three major alleles at the Duffy (FY) blood group locus using polymerase chain reaction with allele-specific primers. *Transfusion*. 1998;38(2):168–73.
22. Tournamille C, Le Van KC, Gane P, Cartron JP, Colin Y. Molecular basis and PCR-DNA typing of the Fya/fyb blood group polymorphism. *Hum Genet*. 1995;95(4):407–10.
23. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected and not benign. *Am J Trop Med Hyg*. 2007;77(6 Suppl):79–87.
24. Orjuela-Sanchez P, da Silva NS, da Silva-Nunes M, Ferreira MU. Recurrent parasitemias and population dynamics of *Plasmodium vivax* polymorphisms in rural Amazonia. *Am J Trop Med Hyg*. 2009;81(6):961–8.
25. Baird JK. Severe and fatal vivax malaria challenges “benign tertian malaria” dogma. *Ann Trop Paediatr*. 2009;29(4):251–2.
26. Jilma-Stohlawetz P, Homoncik M, Drucker C, Marsik C, Rot A, Mayr WR, et al. Fy phenotype and gender determine plasma levels of monocyte chemotactic protein. *Transfusion*. 2001;41(3):378–81.
27. Fukuma N, Akimitsu N, Hamamoto H, Kusuhara H, Sugiyama Y, Sekimizu K. A role of the Duffy antigen for the maintenance of plasma chemokine concentrations. *Biochem Biophys Res Commun*. 2003;303(1):137–9.
28. Schnabel RB, Baumert J, Barbalic M, Dupuis J, Ellinor PT, Durda P, et al. Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators. *Blood*. 2010;115(26):5289–99.
29. Xiong Z, Cavaretta J, Qu L, Stolz DB, Triulzi D, Lee JS. Red blood cell micro-particles show altered inflammatory chemokine binding and release ligand upon interaction with platelets. *Transfusion*. 2011;51(3):610–21.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

